European Commission granted approval of darolutamide in combination with androgen deprivation therapy (ADT) for patients with metastatic hormone-sensitive prostate cancer (mHSPC)
This marks the fourth acquisition by Corona Remedies from multinational corporations
Celecoxib is a nonsteroidal anti-inflammatory drug
The UK authorization is based on positive results from the Phase III OASIS-1, -2, and -3 trials
Xtandi is approved in over 80 countries, including the U.S., EU, and Japan
India’s fertility rate has dropped to 1.9, below the replacement level of 2.1
Masitinib is targeted at patients who are no longer responding to hormone-sensitive prostate cancer treatments
Vevzuo is authorized for the prevention of skeletal related events in adults with advanced malignancies involving bone
Multiple studies show the combination potential of vedotin antibody-drug conjugates (ADCs) with pembrolizumab, including the first Phase 1 data in thoracic cancers for two first-in-class ADCs
Approval brings AstraZeneca and Daiichi Sankyo’s Enhertu earlier in the treatment of HR-positive, HER2-low breast cancer and broadens the eligible patient population to those with HER2-ultralow disease
Subscribe To Our Newsletter & Stay Updated
